Myrexis Inc
OTC:MYRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Myrexis Inc
OTC:MYRX
|
US |
|
M
|
Minto Metals Corp
XTSX:MNTO
|
CA |
|
Brookfield Business Partners LP
TSX:BBU.UN
|
BM |
|
Australia and New Zealand Banking Group Ltd
ASX:ANZ
|
AU |
|
M
|
Manulife US Real Estate Investment Trust
SGX:BTOU
|
SG |
|
E
|
ED Invest SA
WSE:EDI
|
PL |
|
Edimax Technology Co Ltd
TWSE:3047
|
TW |
Myrexis Inc
Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2009-06-12. The firm was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The firm determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The firm operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.
Myrexis, Inc. is in the process of evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets. The company is headquartered in New York City, New York and currently employs 1 full-time employees. The company went IPO on 2009-06-12. The firm was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The firm determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The firm operates in pharmaceutical development and related research activities. The Company’s revenues were derived from research performed in the United States and, all of the Company’s long-lived assets are located in the United States.
